Erleada-ADT Combo Increases Survival of mCSPC Patients Without Affecting Quality of Life, Phase 3 Trial Shows

Erleada-ADT Combo Increases Survival of mCSPC Patients Without Affecting Quality of Life, Phase 3 Trial Shows
Adding Erleada (apalutamide) to standard androgen deprivation therapy (ADT) increases the survival and delays disease progression in men with metastatic castration-sensitive prostate cancer (mCSPC) — and does so without compromising their quality of life — a Phase 3 clinical trial shows. Those findings were presented in the poster, “Patient-reported outcomes (PROs) from TITAN: A phase III, randomized, double-blind study of apalutamide (APA) versus placebo (PBO) added to androgen deprivation therapy (ADT) in patients (pts) with metastatic castration-sensitive prostate cancer (mCSPC),” at the European Society for Medical Oncology (ESMO) 2019 Congress, Sept. 27–Oct. 1 in Barcelona, Spain. The results also were published in The Lancet Oncology. Erleada, developed by Janssen, is a form of hormone therapy that is
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *